



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/51, A61K 39/29 G01N 33/576, C07K 7/00 C12Q 1/68, 1/70	A1	(11) International Publication Number: WO 93/17111 (43) International Publication Date: 2 September 1993 (02.09.93)
(21) International Application Number: PCT/GB93/00410 (22) International Filing Date: 26 February 1993 (26.02.93) (30) Priority data: 9204274.6 28 February 1992 (28.02.92) GB (71) Applicant (for all designated States except US): THE WELL-COME FOUNDATION LIMITED [GB/GB]; Unicorn House, 160 Euston Road, London NW1 2BP (GB). (72) Inventor; and (75) Inventor/Applicant (for US only) : PIKE, Ian [GB/GB]; 8 Cowper Road, Bromley, Kent. BR2 9RX (GB). (74) Agent: EVERETT, Susan, Jane; Elkington and Fife, Prospect House, 8 Pembroke Road, Sevenoaks, Kent TN13 1XR (GB).		(81) Designated States: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, SK, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: HEPATITIS C VIRUS PEPTIDES (57) Abstract This invention relates to a novel peptide, having the sequence as shown in SEQ ID NO's: 1 and 2, capable of binding to antibody specific for parenterally transmitted non-A non-B hepatitis (PT-NANBH), in particular (HCV) and the use of such a peptide in an immunoassay for the detection of HCV or a vaccine for its prevention.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

HEPATITIS C VIRUS PEPTIDES

This invention relates to a novel peptide capable of binding to antibody specific for parenterally transmitted non A non B hepatitis (PT-NANBH) in particular (HCV) and the use of such a peptide in an immunoassay for the detection of HCV or a vaccine for its prevention.

Non A non B hepatitis (NANBH) is by definition a diagnosis of exclusion and has generally been employed to describe cases of viral hepatitis infection in human beings that are not due to hepatitis A or B viruses. The PT-NANBH virus has also been referred to as Hepatitis C Virus (HCV). In the majority of such cases, the cause of the infection has not been identified although, on clinical and epidemiological grounds, a number of agents have been thought to be responsible as reviewed in Shih et al (Prog Liver Dis., 1986, 8, 433-452). In the USA alone, up to 10% of blood transfusions can result in NANBH which makes it a significant problem.

GB-A-2 239 245 discloses nucleotide and polypeptide sequences of a viral agent responsible for Post Transfusional NANBH (PT-NANBH), the core region of this viral agent responsible for PT-NANBH is disclosed within the nucleotide and peptide sequences. The core region of the disclosed viral agent responsible for PT-NANBH was not analysed in GB-A-2 239 245. Substantial portions of the core region were used in recombinant polypeptides namely BHC-11 as disclosed in GB-A-2 239 245.

Substantial regions of the core region of the viral agent responsible for PT-NANBH disclosed in GB-A-2 239 245, were also used to detect HCV infection in British Application No. 9203803.3 filed in the name of Wellcome Foundation Limited on February 21, 1992.

EP-A-0 445 423 discloses an assay for detecting the

presence of an antibody to an HCV antigen by contacting the sample with a polypeptide containing at least one epitope of an HCV antigen. A polypeptide from the putative core region of HCV is used. Specific epitopic regions of the polypeptides are
5 not identified.

It has surprisingly been found by the present inventors that several domains within the N-terminal region of the HCV core protein are epitopic. It has also surprisingly been found
10 that of the sera reactive with N-terminal region of the core protein the majority react with a single domain exclusively or in combination with any of the other epitopic domains. This single domain has been termed the immunodominant epitope. This immunodominant epitope has been isolated by the present
15 inventors.

Accordingly, the present invention provides a HCV viral peptide having the following sequence (SEQ ID NO's: 1 and 2):

Tyr-Leu-Leu-Pro-Arg-Arg (YLLPRR)

20

This sequence may be found at residues 35-40 of the core protein. The present invention also provides a DNA sequence encoding the peptide as defined above. The DNA sequence may be synthetic or cloned. Preferably the DNA sequence is as set
25 forth in SEQ ID NO:1.

A novel synthetic peptide has also been synthesised which peptide has improved assay sensitivity and specificity, when compared to the natural peptide as disclosed above, in assays
30 for HCV.

Accordingly, the present invention also provides a peptide of the general formula I

$X_1-X_2-X_3-X_4-X_5-X_6$ (SEQ ID NO: 3) I

35 wherein;

X_1 represents Tyrosine, Aspartic Acid, Glutamic Acid, Leucine or Isoleucine;

X₂ represents Leucine, Cysteine, Aspartic Acid or Glutamic Acid;

X₃ represents Leucine, Valine;

X₄ represents Proline or Methionine;

5 X₅ represents Arginine, Aspartic Acid, Glutamic Acid, Proline, Cysteine, Phenylalanine, Isoleucine, Asparagine, Glutamine or Methionine; and

X₆ represents Arginine, Aspartic Acid, Glutamic Acid, Serine or Cysteine

10 and wherein the peptide is not of the formula Tyr-Leu-Leu-Pro-Arg-Arg (SEQ ID NO: 1 and 2).

The present invention also provides a DNA sequence encoding the peptide of general formula I, which sequence can
15 be readily ascertained, bearing in mind the degeneracy of the genetic code and codon usage.

The peptides of the present invention may be used individually, as part of a larger polypeptide and/or as a
20 mixture of peptides with other peptides from the HCV genome, a heterologous genome or topographically related peptides.

The present invention also provides peptides which comprise the peptides as defined above, namely, SEQ ID NO's: 4
25 and 5 and SEQ ID NO's: 6 and 7.

The present invention also provides DNA sequences encoding the peptide as set forth above. Preferably the DNA sequences are as set forth in SEQ ID NO's: 4 and 6.
30

The present invention also provides expression vectors containing the DNA sequences as herein defined, which vectors being capable, in an appropriate host, of expressing the DNA sequence to produce the peptides as defined herein.
35

The expression vector normally contains control elements of DNA that effect expression of the DNA sequence in an

appropriate host. These elements may vary according to the host but usually include a promoter, ribosome binding site, translational start and stop sites, and a transcriptional termination site. Examples of such vectors include plasmids and viruses. Expression vectors of the present invention encompass both extrachromosomal vectors and vectors that are integrated into the host cell's chromosome. For use in E.coli, the expression vector may contain the DNA sequence of the present invention optionally as a fusion linked to either the 5'- or 3'-end of the DNA sequence encoding, for example, β -galactosidase or to the 3'-end of the DNA sequence encoding, for example, the trp E gene. For use in the insect baculovirus (AcNPV) system, the DNA sequence is optionally fused to the polyhedrin coding sequence.

15

The present invention also provides a host cell transformed with expression vectors as herein defined.

Examples of host cells of use with the present invention include prokaryotic and eukaryotic cells, such as bacterial, yeast, mammalian and insect cells. Particular examples of such cells are E.coli, S.cerevisiae, P.pastoris, Chinese hamster ovary and mouse cells, and Spodoptera frugiperda and Tricoplusia ni. The choice of host cell may depend on a number of factors but, if post-translational modification of the HCV viral peptide is important, then an eukaryotic host would be preferred.

The present invention also provides a process for preparing a peptides as defined herein which comprises isolating the DNA sequence, as herein defined, from the HCV genome, or synthesising DNA sequence encoding the peptides as defined herein, or generating a DNA sequence encoding the peptide of Formula I, inserting the DNA sequence into an expression vector such that it is capable, in an appropriate host, of being expressed, transforming an host cells with the expression vector, culturing the transformed host cells, and

isolating the peptide.

The DNA sequence encoding the peptide may be synthesised using standard procedures (Gait, Oligonucleotide Synthesis: A
5 Practical Approach, 1984, Oxford, IRL Press).

The desired DNA sequence obtained as described above may be inserted into an expression vector using known and standard techniques. The expression vector is normally cut using
10 restriction enzymes and the DNA sequence inserted using blunt-end or staggered-end ligation. The cut is usually made at a restriction site in a convenient position in the expression vector such that, once inserted, the DNA sequences are under the control of the functional elements of DNA that effect its
15 expression.

Transformation of an host cell may be carried out using standard techniques. Some phenotypic marker is usually employed to distinguish between the transformants that have
20 successfully taken up the expression vector and those that have not. Culturing of the transformed host cell and isolation of the peptide as required may also be carried out using standard techniques.

25 The peptides of the present invention may be prepared by synthetic methods or by recombinant DNA technology. The peptides are preferably synthesized using automatic synthesizers.

30 Antibody specific to a peptide of the present invention can be raised using the peptide. The antibody may be polyclonal or monoclonal. The antibody may be used in quality control testing of batches of the peptides; purification of a peptide or viral lysate; epitope mapping; when labelled, as a
35 conjugate in a competitive type assay, for antibody detection; and in antigen detection assays.

Polyclonal antibody against a peptide of the present invention may be obtained by injecting a peptide, optionally coupled to a carrier to promote an immune response, into a mammalian host, such as a mouse, rat, sheep or rabbit, and recovering the antibody thus produced. The peptide is generally administered in the form of an injectable formulation in which the peptide is admixed with a physiologically acceptable diluent. Adjuvants, such as Freund's complete adjuvant (FCA) or Freund's incomplete adjuvant (FIA), may be included in the formulation. The formulation is normally injected into the host over a suitable period of time, plasma samples being taken at appropriate intervals for assay for anti-HCV viral antibody. When an appropriate level of activity is obtained, the host is bled. Antibody is then extracted and purified from the blood plasma using standard procedures, for example, by protein A or ion-exchange chromatography.

Monoclonal antibody against a peptide of the present invention may be obtained by fusing cells of an immortalising cell line with cells which produce antibody against the viral or topographically related peptide, and culturing the fused immortalised cell line. Typically, a non-human mammalian host, such as a mouse or rat, is inoculated with the peptide. After sufficient time has elapsed for the host to mount an antibody response, antibody producing cells, such as the splenocytes, are removed. Cells of an immortalising cell line, such as a mouse or rat myeloma cell line, are fused with the antibody producing cells and the resulting fusions screened to identify a cell line, such as a hybridoma, that secretes the desired monoclonal antibody. The fused cell line may be cultured and the monoclonal antibody purified from the culture media in a similar manner to the purification of polyclonal antibody.

Diagnostic assays based upon the present invention may be used to determine the presence or absence of HCV infection. They may also be used to monitor treatment of such infection, for example in interferon therapy.

In an assay for the diagnosis of viral infection, there are basically three distinct approaches that can be adopted involving the detection of viral nucleic acid, viral antigen or viral antibody. Viral nucleic acid is generally regarded as the best indicator of the presence of the virus itself and would identify materials likely to be infectious. However, the detection of nucleic acid is not usually as straightforward as the detection of antigens or antibodies since the level of target can be very low. Viral antigen is used as a marker for the presence of virus and as an indicator of infectivity. Depending upon the virus, the amount of antigen present in a sample can be very low and difficult to detect. Antibody detection is relatively straightforward because, in effect, the host immune system is amplifying the response to an infection by producing large amounts of circulating antibody. The nature of the antibody response can often be clinically useful, for example IgM rather than IgG class antibodies are indicative of a recent infection, or the response to a particular viral antigen may be associated with clearance of the virus. Thus the exact approach adopted for the diagnosis of a viral infection depends upon the particular circumstances and the information sought. In the case of HCV, a diagnostic assay may embody any one of these three approaches.

In an assay for the diagnosis of HCV involving detection of viral nucleic acid, the method may comprise hybridising viral RNA present in a test sample, or cDNA synthesised from such viral RNA, with a DNA sequence corresponding to the nucleotide sequence of SEQ ID NO: 1, 4 or 6 or encoding the peptide of formula I and screening the resulting nucleic acid hybrids to identify any HCV viral nucleic acid. The application of this method is usually restricted to a test sample of an appropriate tissue, such as a liver biopsy, in which the viral RNA is likely to be present at a high level. The DNA sequence corresponding to the nucleotide sequence of SEQ ID NO: 1, 4 or 6 or encoding the peptide of Formula I may take the form of an oligonucleotide or a cDNA sequence

sequence optionally contained within a plasmid. Screening of the nucleic acid hybrids is preferably carried out by using a labelled DNA sequence. Preferably the peptide of the present invention is part of an oligonucleotide wherein the label is
5 situated at a sufficient distance from the peptide so that binding of the peptide to the viral nucleic acid is not interfered with by virtue of the label being too close to the binding site. One or more additional rounds of screening of one kind or another may be carried out to characterise further
10 the hybrids and thus identify any HCV viral nucleic acid. The steps of hybridisation and screening are carried out in accordance with procedures known in the art.

The present invention also provides a test kit for the
15 detection of HCV viral nucleic acid, which comprises

- i) a labelled oligonucleotide comprising a DNA sequence corresponding to the nucleotide sequence of SEQ ID NO: 1, 4 or 6 or encoding the peptide of formula I; and
20 optionally;
- ii) washing solutions, reaction buffers and a substrate, if the label is an enzyme.

25 Advantageously, the test kit also contains a positive control sample to facilitate in the identification of viral nucleic acid.

In an assay for the diagnosis of HCV involving detection
30 of viral antigen or antibody, the method may comprise contacting a test sample with a peptide of the present invention or a polyclonal or monoclonal antibody against the peptide and determining whether there is any antigen-antibody binding contained within the test sample. For this purpose, a
35 test kit may be provided comprising a peptide, as defined herein, or a polyclonal or monoclonal antibody thereto and means for determining whether there is any binding with

antibody or antigen respectively contained in the test sample. The test sample may be taken from any of the appropriate tissues and physiological fluids mentioned above for the detection of viral nucleic acid. If a physiological fluid is obtained, it may optionally be concentrated for any viral antigen or antibody present.

A variety of assay formats may be employed. The peptide can be used to capture selectively antibody against HCV from solution, to label selectively the antibody already captured, or both to capture and label the antibody. In addition, the peptide may be used in a variety of homogeneous assay formats in which the antibody reactive with the peptide is detected in solution with no separation of phases.

15

The types of assay in which the peptide is used to capture antibody from solution involve immobilization of the peptide on to a solid surface. This surface should be capable of being washed in some way. Examples of suitable surfaces include polymers of various types (moulded into microtitre wells; beads; dipsticks of various types; aspiration tips; electrodes; and optical devices), particles (for example latex; stabilized red blood cells; bacterial or fungal cells; spores; gold or other metallic or metal-containing sols; and proteinaceous colloids) with the usual size of the particle being from 0.02 to 5 microns, membranes (for example of nitrocellulose; paper; cellulose acetate; and high porosity/high surface area membranes of an organic or inorganic material).

30

The attachment of the peptide to the surface can be by passive adsorption from a solution of optimum composition which may include surfactants, solvents, salts and/or chaotropes; or by active chemical bonding. Active bonding may be through a variety of reactive or activatable functional groups which may be exposed on the surface (for example condensing agents; active acid esters, halides and anhydrides; amino, hydroxyl, or

35

carboxyl groups; sulphhydryl groups; carbonyl groups; diazo groups; or unsaturated groups). Optionally, the active bonding may be through a protein (itself attached to the surface passively or through active bonding), such as albumin or casein, to which the viral peptide may be chemically bonded by any of a variety of methods. The use of a protein in this way may confer advantages because of isoelectric point, charge, hydrophilicity or other physico-chemical property. The viral peptide may also be attached to the surface (usually but not necessarily a membrane) following electrophoretic separation of a reaction mixture, such as immuno precipitation.

After contacting (reacting) the surface bearing the peptide with a test sample, allowing time for reaction, and, where necessary, removing the excess of the sample by any of a variety of means, (such as washing, centrifugation, filtration, magnetism or capillary action) the captured antibody is detected by any means which will give a detectable signal. For example, this may be achieved by use of a labelled molecule or particle as described above which will react with the captured antibody (for example protein A or protein G and the like; anti-species or anti-immunoglobulin-sub-type; rheumatoid factor; or antibody to the peptide, used in a competitive or blocking fashion), or any molecule containing an epitope contained in the peptide.

The detectable signal may be optical or radioactive or physico-chemical and may be provided directly by labelling the molecule or particle with, for example, a dye, radiolabel, electroactive species, magnetically resonant species or fluorophore, or indirectly by labelling the molecule or particle with an enzyme itself capable of giving rise to a measurable change of any sort. Alternatively the detectable signal may be obtained using, for example, agglutination, or through a diffraction or birefringent effect if the surface is in the form of particles.

Assays in which a peptide itself is used to label an already captured antibody require some form of labelling of the peptide which will allow it to be detected. The labelling may be direct by chemically or passively attaching for example a
5 radio label, magnetic resonant species, particle or enzyme label to the peptide; or indirect by attaching any form of label to a molecule which will itself react with the peptide. The chemistry of bonding a label to the peptide can be directly through a moiety already present in the peptide, such as an
10 amino group, or through an intermediate moiety, such as a maleimide group. Capture of the antibody may be on any of the surfaces already mentioned by any reagent including passive or activated adsorption which will result in specific antibody or immune complexes being bound. In particular, capture of the
15 antibody could be by anti-species or anti-immunoglobulin-subtype, by rheumatoid factor, proteins A, G and the like, or by any molecule containing an epitope contained in the peptide.

The labelled peptide may be used in a competitive binding
20 fashion in which its binding to any specific molecule on any of the surfaces exemplified above is blocked by antigen in the sample. Alternatively, it may be used in a non-competitive fashion in which antigen in the sample is bound specifically or non-specifically to any of the surfaces above and is also bound
25 to a specific bi- or poly-valent molecule (e.g. an antibody) with the remaining valencies being used to capture the labelled peptide.

Often in homogeneous assays the peptide and an antibody
30 are separately labelled so that, when the antibody reacts with the recombinant peptide in free solution, the two labels interact to allow, for example, non-radiative transfer of energy captured by one label to the other label with appropriate detection of the excited second label or quenched
35 first label (e.g. by fluorimetry, magnetic resonance or enzyme measurement). Addition of either viral peptide or antibody in a sample results in restriction of the interaction of the

labelled pair and thus in a different level of signal in the detector.

A suitable assay format for detecting HCV antibody is the
5 direct sandwich enzyme immunoassay (EIA) format. A peptide is
coated onto microtitre wells. A test sample and a peptide to
which an enzyme is coupled are added simultaneously. Any HCV
antibody present in the test sample binds both to the peptide
10 coating the well and to the enzyme-coupled peptide. Typically,
the same peptide are used on both sides of the sandwich. After
washing, bound enzyme is detected using a specific substrate
involving a colour change. A test kit for use in such an EIA
comprises:

- 15 (1) a peptide, as herein defined labelled with an enzyme;
- (2) a substrate for the enzyme;
- (3) means providing a surface on which a peptide is
20 immobilised; and
- (4) optionally, washing solutions and/or buffers.

It is also possible to use IgG/IgM antibody capture ELISA
25 wherein an antihuman antibody is coated onto microlitre wells,
a test sample is added to the well. Any IgG or IgM antibody
present in the test sample will then bind to the anti-human
antibody. A peptide of the present invention, which has been
labelled, is added to the well and the peptide will bind to any
30 IgG or IgM antibody which has resulted due to infection by HCV.
The IgG or IgM antibody can be visualized by virtue of the
label on the peptide.

It can thus be seen that the peptides of the present
35 invention may be used for the detection of HCV infection in
many formats, namely as free peptides, in assays including
classic ELISA, competition ELISA, membrane bound EIA and

immunoprecipitation. Peptide conjugates may be used in amplified assays and IgG/IgM antibody capture ELISA.

The peptide of the present invention may be incorporated
5 into a vaccine formulation for inducing immunity to HCV in man. For this purpose the peptide may be presented in association with a pharmaceutically acceptable carrier.

For use in a vaccine formulation, the peptide may
10 optionally be presented as part of an hepatitis B core fusion particle, as described in Clarke *et al* (*Nature*, 1987, 330, 381-384), or a polylysine based polymer, as described in Tam (*PNAS*, 1988, 85, 5409-5413). Alternatively, the peptide may optionally be attached to a particulate structure, such as
15 liposomes or ISCOMS.

Pharmaceutically acceptable carriers include liquid media suitable for use as vehicles to introduce the peptide into a patient. An example of such liquid media is saline solution.
20 The peptide may be dissolved or suspended as a solid in the carrier.

The vaccine formulation may also contain an adjuvant for stimulating the immune response and thereby enhancing the
25 effect of the vaccine. Examples of adjuvants include aluminium hydroxide and aluminium phosphate.

The vaccine formulation may contain a final concentration of peptide in the range from 0.01 to 5 mg/ml, preferably from
30 0.03 to 2 mg/ml. The vaccine formulation may be incorporated into a sterile container, which is then sealed and stored at a low temperature, for example 4°C, or may be freeze-dried.

In order to induce immunity in man to HCV, one or more
35 doses of the vaccine formulation may be administered. Each dose may be 0.1 to 2 ml, preferably 0.2 to 1 ml. A method for inducing immunity to HCV in man, comprises the administration

of an effective amount of a vaccine formulation, as hereinbefore defined.

The present invention also provides the use of a peptide
5 as herein defined in the preparation of a vaccine for use in the induction of immunity to HCV in man.

Vaccines of the present invention may be administered by any convenient method for the administration of vaccines
10 including oral and parenteral (e.g. intravenous, subcutaneous or intramuscular) injection. The treatment may consist of a single dose of vaccine or a plurality of doses over a period of time.

15 In the sequence listing, there are listed SEQ ID NO: 1 to 29 to which reference is made in the description and claims.

The embodiments of the invention will now be illustrated.

20 Example 1: Identification of Epitopic domain of the HCV Core protein

The N-terminal 97 amino acid residues of HCV Core protein SEQ ID NO: 8 was mapped with PEPSCAN analysis. This process
25 involved the serological analysis of sequentially overlapping peptides which spanned the region of interest, to identify epitopic domains. Ninety overlapping octameric peptides were synthesized on polypropylene pin supports according to the manufacturer's instructions (Cambridge Research Biochemicals),
30 such that each peptide overlapped with the preceding sequence by the seven N-terminal residues, and with the subsequent peptide by the seven C-terminal residues. Serum or IgG purified from the serum of individuals confirmed to be seropositive for HCV were used to screen the peptides.

Example 2: Screening of the Peptides

The assay procedure followed was performed basically as described in the manufacturers instruction manual. The time and temperature of the test antibody incubation differed from that prescribed, thereby decreasing the time taken for each assay.

Sera: A total of 16 sera were assayed by PEPSCAN. These consisted of 12 sera from paid U.S. Donors which were identified as being positive for antibodies against HCV in routine screening at the site of donation. The remaining four sera were from patients diagnosed as having non-A non-B hepatitis, and which were subsequently shown to contain antibodies to HCV. Sera were screened either as the crude serum fraction, or as a caprylic acid preparation. Caprylic acid purification of IgG from the sera was performed as described by Stienbuch and Audran (1969) Arch. Biochem. Biophys. 134, 279-284.

20

Assay: The assay format involves sequentially incubating the various pins in microwell plates containing blocking, test antibody, conjugate, and substrate solutions. The immune complex builds up on the pin with the enzyme labelled conjugate being immobilized on the bound anti-peptide antibody from the test serum. When the pin is then immersed in substrate, the enzyme brings about the colour change which is used to quantify the amount of anti-peptide antibody bound.

Blocking: Pins are immersed in 200 μ l of Supercocktail (1% Ovalbumin, 1% bovine serum albumin in 0.15M phosphate buffered saline pH 7.2 + 0.1% Tween 20) and left to stand at room temperature for 1 hour.

Test antibody: The test antibody is diluted between 1/200 (IgG) and 1/1000 (serum) in supercocktail. The pins are then stood in this solution (175 μ l/well) at 37°C for 1 hour.

After this incubation the pins are washed four times in 0.15M phosphate buffered saline pH 7.2 + 0.05% Tween 20, each at room temperature for 10 minutes.

5 Conjugate: Rabbit anti-human IgG coupled to horseradish peroxidase is diluted 1/1000 in supercocktail. The peptide bearing pins are then stood in this solution at room temperature for 1 hour. Once again the pins are then washed four times as above.

10

Substrate: The substrate solution is made up fresh for each assay. To 100ml of 0.1M phosphate, 0.08M citrate buffer pH 4.0 is dissolved 50mg of 2,2'-AZINO-bis(3-ethylbenzthiazolinsulphonic acid (ABTS) and 0.3µl/ml 30% hydrogen peroxide is
15 added. The pins are immersed in the wells containing substrate solution (150µl/well) and incubated at room temperature in the dark. Once sufficient colour has developed the reaction is stopped by removing the pins. The plates are then read immediately in a spectrophotometric plate reader at a
20 wavelength of 405nm. The absorbance values are then plotted against pin number. The epitopic domains are then defined as the continuous sequence of amino acids common to all positive pins in the domain i.e.

25	Positive Pin 1	Gly-Val-Tyr-Leu-Leu-Pro-Arg-Arg	(SEQ ID
		(G V Y L L P R R)	NO: 9)
	Positive Pin 2	Val-Tyr-Leu-Leu-Pro-Arg-Arg-Gly	(SEQ ID
		(V Y L L P R R G)	NO: 10)
	Positive Pin 3	Tyr-Leu-Leu-Pro-Arg-Arg-Gly-Pro	(SEQ ID
30		(Y L L P R R G P)	NO: 11)

In this example the epitope has the sequence Tyr-Leu-Leu-Pro-Arg-Arg (YLLPRR) (SEQ ID NO's: 1 and 2).

35 Cleaning: After use the pins are cleaned by ultrasonication in disruption buffer (1% sodium dodecyl sulphate, 0.1% 2-mercaptoethanol in 0.1M sodium dihydrogen phosphate) heated to

60°C. Pins are sonicated for 30 minutes and then washed twice in distilled water at 60°C and once in boiling methanol. Pins can then be stored at room temperature sealed in bags containing silica gel, or can be re-used immediately for the next assay.

Several domains within the N-terminal region of HCV Core protein were thus identified as being epitopic. One of these regions, the immunodominant epitope, was detected to a greater or lesser extent by all of the sera tested. The immunodominant epitope is situated from residues 35-40 of the Core protein having the amino acid sequence Tyr-Leu-Leu-Pro-Arg-Arg (YLLPRR) SEQ ID NO's 1 and 2. Sample assay results are shown in Table 1.

Table 1:

Absorbance Units for different sera						
Peptide	SEQ ID NO	65221	65241	65276	65234	L
GGGQIVGG	12	137	121	127	134	121
GGQIVGGV	13	323	122	119	179	119
GQIVGGVY	14	216	112	128	165	138
QIVGGVYL	15	329	125	165	152	161
IVGGVYLL	16	268	126	183	186	158
VGGVYLLP	17	83	144	182	235	169
GGVYLLPR	18	132	311	246	344	191
GVYLLPRR	19	613	511	350	229	378
VYLLPRRG	20	769	641	440	280	306
YLLPRRG	21	332	367	248	177	242
LLPRRGPR	22	142	129	98	101	133
LPRRGPR	23	97	94	139	145	148
PRRGPR	24	85	73	129	109	110
RRGPRLGV	25	145	85	150	146	123
RGPRLGVR	26	168	94	167	99	132
GPRLGVRA	27	111	60	146	75	101
PRLGVRAT	28	166	79	155	88	115
RLGVRATR	29	81	180	177	100	124

The amino acid residues are denoted by the single letter code (Eur. J. Biochem. 138, 9-37. 1984). The underlined characters represent the immunodominant region.

5

Example 3: Preparation of novel mimic of original Epitope

The Replacement Net Method was used to sequentially replace each of the constituent amino acid residues in the
10 epitope with each of the other genetically encoded amino acids.

For Replacement Net analysis, a parent sequence is entered into the Epitope Mapping Software provided by Cambridge Research Biochemicals, and a set of replacement peptides is
15 generated. This process was performed for the six amino acid residue immunodominant core epitope of HCV. The peptides were synthesized on polypropylene pins as directed by the manufacturer (CRB). The Assay format was identical to that followed for PEPSCAN above.

20

The Replacement Net of the core immunodominant epitope sequence Tyr-Leu-Leu-Pro-Arg-Arg (YLLPRR) (SEQ ID NO: 1 AND 2) with the 12 paid donor human sera as described above was considered.

25

For each position within the epitope, the frequency of each replacement residue as an acceptable replacement for the parent sequence is given. Replacement residues were deemed acceptable when the signal of the new peptide was 80% of the
30 parent sequence or greater.

Based on these results, the substitute amino acid residues at each position, which are most likely potentiating substitutions, can be obtained. These are shown in Table 2.
35 The residue in italics is the parent sequence.

Table 2:

5

Parent Residue	Amino Acid	Frequency of relative signal strength (n=12)				
		Highest	2nd-5th	6th-10th	Below 10th	All
10 1-Tyrosine	D	1	8	1	0	10
	E	2	8	1	0	11
	I	0	3	7	0	10
	L	7	1	1	0	9
	Y	2	3	5	1	11
15						
20 2-Leucine	C	2	8	1	0	11
	D	6	4	0	0	10
	E	1	6	4	0	11
	L	1	2	3	2	8
25						
3-Leucine	L	2	0	1	0	3
	V	6	5	0	0	11
30						
4-Proline	M	4	5	0	0	9
	P	3	1	1	0	5

Table 2 (continued)

5	Parent Residue	Amino Acid	Frequency of relative signal strength (n=12)					All
			Highest	2nd-5th	6th-10th	Below 10th		
10	5-Arginine	C	0	8	2	0	10	
		D	4	5	1	1	11	
		E	2	4	3	1	10	
		F	0	2	7	3	12	
		M	0	2	2	6	10	
		N	0	0	6	5	11	
15		P	1	5	4	1	11	
		Q	2	6	2	0	10	
		R	0	2	1	7	10	
20	6-Arginine	C	0	4	0	6	10	
		D	3	2	3	2	10	
		E	1	6	2	1	10	
		R	2	1	5	3	11	
25		S	3	5	1	1	10	

Example 4: Preparation of AC 22

Fully protected peptide-resin was assembled on a p-hydroxymethylphenoxymethyl (HMP) resin by stepwise solid phase synthesis (proceeding from the carboxyl terminal residue towards the amino terminal residue) according to the general procedure set out in Applied Biosystems User Bulletin No 33, November 1990. HMP resin was transferred into the reaction vessel of an Applied Biosystems Peptide Synthesizer Model 431A. The carboxyl-terminal amino acid residue was coupled to the resin using the standard Applied Biosystems Fastmoc cycle protocol. Unreacted coupling sites on the resin were then blocked by capping with benzoic anhydride. All subsequent amino acids were then added in a stepwise manner moving from the carboxyl terminus to the amino terminus using the *Fastmoc* cycle protocol. The N- α -amino group of all peptides was protected by the 9-fluorophenylmethoxycarbonyl (Fmoc) linkage. Side chain functional groups of the relevant amino acids were protected by the following groups

- Cys-Trt (Trityl)
- Gly-Trt (Trityl)
- Tyr-tBu (Tert. Butyl)
- Arg-Pmc (2,2,5,7,8-pentamethylchroman-6-sulphonyl)

The fully protected peptide-resin was transferred to a pear-shaped flask and treated with ethanedithiol (0.25 ml), thioanisole (0.5 ml), water (0.5 ml) and TFA (8.75 ml). The mixture was stirred for 90 minutes at room temperature, then filtered through glass wool in a Pasteur pipette. The filtrate was dropped into ice-cold ether, contained in a Corex centrifuge tube, whereupon the peptide precipitated. The tube was centrifuged and the liquor aspirated to leave the peptide pellet in the tube. The peptide was washed with ether (using a spatula to dis-aggregate the pellet and the peptide recovered by centrifugation. This was repeated a total of six times. The peptide was finally dried by centrifugation *in vacuo*.

Example 5: Vaccine Formulation

A vaccine formulation may be prepared by conventional techniques using the following constituents in the indicated amounts.

10	HCV viral peptide (whether alone, as a longer polypeptide or with a cocktail of other peptides)	>	0.36 mg
	Thiomersal	0.04 - 0.2	mg
	Sodium Chloride	<	8.5 mg
	Water	<	1 ml

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT:

- (A) NAME: The Wellcome Foundation Limited
(B) STREET: Unicorn House, 160 Euston Road,
(C) CITY: London
(E) COUNTRY: Great Britain
(F) POSTAL CODE (ZIP): NW1 2BP

10

(ii) TITLE OF INVENTION: Novel Peptides

15 (iii) NUMBER OF SEQUENCES: 29

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

20

(2) INFORMATION FOR SEQ ID NO: 1:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 1..18

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

40 TAC TTG TTG CCG CGC AGG
Tyr Leu Leu Pro Arg Arg
1 5

18

(2) INFORMATION FOR SEQ ID NO: 2:

45

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

55 Tyr Leu Leu Pro Arg Arg
1 5

24

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION: one-of(1)
15 (D) OTHER INFORMATION: /note= "Xaa represents Tyr, Asp,
Glu, Leu or Ile"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
(B) LOCATION: one-of(2)
20 (D) OTHER INFORMATION: /note= "Xaa represents Leu, Cys,
Asp or Glu"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
25 (B) LOCATION: one-of(3)
(D) OTHER INFORMATION: /note= "Xaa represents Leu or Val"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
30 (B) LOCATION: one-of(4)
(D) OTHER INFORMATION: /note= "Xaa represents Pro or Met"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
35 (B) LOCATION: one-of(5)
(D) OTHER INFORMATION: /note= "Xaa represents Arg, Asp,
Glu, Pro, Cys, Phe, Ile, Asn, Gln or Met"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
40 (B) LOCATION: one-of(6)
(D) OTHER INFORMATION: /note= "Xaa represents Arg, Asp,
Glu, Ser or Cys"

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Xaa Xaa Xaa Xaa Xaa Xaa
1 5

50

25

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 51 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

10

(ix) FEATURE:

- 15 (A) NAME/KEY: CDS
 (B) LOCATION: 1..51
 (D) OTHER INFORMATION: /note= "Nucleotides 1-3 are of
 non-HCV origin"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

20

TGC CAG ATC GTT GGT GGA GTT TAC TTG TTG CCG CGC AGG GGC CCT AGA 48
 Cys Gln Ile Val Gly Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg
 1 5 10 15

25 TTG
 Leu

51

30 (2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 17 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

40

Cys Gln Ile Val Gly Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg
 1 5 10 15

45 Leu

26

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 51 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

10

(ix) FEATURE:

- 15 (A) NAME/KEY: CDS
 (B) LOCATION: 1..51
 (D) OTHER INFORMATION: /note= "Nucleotides 49 to 51 are of
 non-HCV origin"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

20

CAG ATC GTT GGT GGA GTT TAC TTG TTG CCG CGC AGG GGC CCT AGA TTG 48
 Gln Ile Val Gly Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu
 1 5 10 15

25 TGC
 Cys

51

30 (2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 17 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

40

Gln Ile Val Gly Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu
 1 5 10 15

45 Cys

27

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

5

(A) LENGTH: 97 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

15

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn
 1 5 10 15

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly
 20 25 30

20

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala
 35 40 45

25

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro
 50 55 60

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly
 65 70 75 80

30

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp
 85 90 95

Leu

35 (2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

40

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

50

Gly Val Tyr Leu Leu Pro Arg Arg
 1 5

28

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Val Tyr Leu Leu Pro Arg Arg Gly
1 5

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Tyr Leu Leu Pro Arg Arg Gly Pro
1 5

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Gly Gly Gly Gln Ile Val Gly Gly
1 5

29

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Gly Gly Gln Ile Val Gly Gly Val
1 5

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Gly Gln Ile Val Gly Gly Val Tyr
1 5

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Gln Ile Val Gly Gly Val Tyr Leu
1 5

30

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Ile Val Gly Gly Val Tyr Leu Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Val Gly Gly Val Tyr Leu Leu Pro
1 5

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region
(B) LOCATION: 4..8
(D) OTHER INFORMATION: /note= "Immunodominant region"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Gly Gly Val Tyr Leu Leu Pro Arg
1 5

31

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

5

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(ix) FEATURE:

(A) NAME/KEY: Region

(B) LOCATION: 3..8

15

(D) OTHER INFORMATION: /note= "Immunodominant region"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

20

Gly Val Tyr Leu Leu Pro Arg Arg
1 5

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30

(ix) FEATURE:

(A) NAME/KEY: Region

(B) LOCATION: 2..7

35

(D) OTHER INFORMATION: /note= "Immunodominant region"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

40

Val Tyr Leu Leu Pro Arg Arg Gly
1 5

32

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(ix) FEATURE:

- (A) NAME/KEY: Region
(B) LOCATION: 1..6
15 (D) OTHER INFORMATION: /note= "Immunodominant region"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

20 Tyr Leu Leu Pro Arg Arg Gly Pro
1 5

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

35 Leu Leu Pro Arg Arg Gly Pro Arg
1 5

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

50

Leu Pro Arg Arg Gly Pro Arg Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

5

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

15

Pro Arg Arg Gly Pro Arg Leu Gly
1 5

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

20

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

30

Arg Arg Gly Pro Arg Leu Gly Val
1 5

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

35

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: unknown

40

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

45

Arg Gly Pro Arg Leu Gly Val Arg
1 5

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

15 Gly Pro Arg Leu Gly Val Arg Ala
1 5

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

30 Pro Arg Leu Gly Val Arg Ala Thr
1 5

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

45

Arg Leu Gly Val Arg Ala Thr Arg
1 5

Claims

1. A HCV viral peptide having the sequence:
Tyr-Leu-Leu-Pro-Arg-Arg (SEQ ID NO's: 1 and 2)
5
2. A peptide having the sequence of the general formula I
 $X_1-X_2-X_3-X_4-X_5-X_6$ (SEQ ID NO: 3) I
wherein;
X₁ represents Tyrosine, Aspartic Acid, Glutamic Acid, Leucine
10 or Isoleucine;
X₂ represents Leucine, Cysteine, Aspartic Acid or Glutamic
Acid;
X₃ represents Leucine, Valine;
X₄ represents Proline or Methionine;
15 X₅ represents Arginine, Aspartic Acid, Glutamic Acid, Proline,
Cysteine, Phenylalanine, Isoleucine, Asparagine, Glutamine or
Methionine; and
X₆ represents Arginine, Aspartic Acid, Glutamic Acid, Serine
or Cysteine
20 and wherein the peptide is not of the formula Tyr-Leu-Leu-Pro-
Arg-Arg (SEQ ID NO: 1 or 2).
3. A viral peptide having as set forth in SEQ ID NO's: 4 and
5 or SEQ ID NO's: 6 and 7.
25
4. A DNA sequence encoding a peptide as claimed in claim 1,
2 or 3.
5. A DNA sequence as claimed in claim 4 as set forth in SEQ
30 ID NO: 1, 4 or 6.
6. An expression vector containing a DNA sequence as claimed
in claim 4 or 5 being capable in an appropriate host of
expressing the DNA sequence to produce a peptide.
35
7. A host cell transformed with an expression vector as
claimed in claim 6.

8. A process for preparing a peptide as claimed in any of claims 1 to 3 which comprises isolating the DNA sequence, as set forth in SEQ ID NO: 1, 4 or 6, from the HCV genome, or synthesising a DNA sequence encoding the peptide, as set forth
5 in SEQ ID NO: 1, 4, 6, or generating a DNA sequence encoding for the peptide of Formula I, inserting the DNA sequence into an expression vector such that it is capable, in an appropriate host, of being expressed, transforming an host cell with the expression vector, culturing the transformed host cell, and
10 isolating the peptide.

9. A process for preparing the peptide as claimed in any of claims 1 to 3 characterized in that it is prepared synthetically.
15

10. A polyclonal or monoclonal antibody against a peptide as claimed in any of claims 1 to 3.

11. A method of the detection of HCV viral nucleic acid which
20 comprises hybridizing viral RNA present in the test sample or cDNA synthesized from such RNA, with a DNA sequence corresponding to SEQ ID NO: 1, 4, 6, or encoding the peptide of formula I and screening the resulting nucleic acid hybrids to identify any HCV viral nucleic acid.
25

12. A method for the detection of HCV viral antibody which comprises contacting a test sample with a peptide as claimed in any of claims 1 to 3 or a polyclonal or monoclonal antibody as claimed in claim 10 and determining whether there is any
30 antigen-antibody binding contained within the test sample.

13. A test kit for the detection of HCV viral antibody which comprises the peptide as claimed in any of claims 1 to 3 or a polyclonal or monoclonal antibody as claimed in claim 10 and
35 means for determining whether there is any antigen-antibody binding contained in the test sample.

14. A vaccine formulation which comprises a peptide as claimed in any of claims 1 to 3 in association with a pharmaceutically acceptable carrier.

- 5 15. A method for inducing immunity in man to HCV which comprises the administration of an effective amount of a vaccine formulation according to claim 14.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 93/00410

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C12N15/51; A61K39/29; G01N33/576; C07K7/00 C12Q1/68; C12Q1/70		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07K ; G01N ; A61K ; C12Q C12N	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	PROC. NAT'L. ACAD. SCI. USA vol. 88, no. 12, 1991, pages 5462 - 5466 M. NASOFF ET AL. 'Identification of an immunodominant epitope within the capsid protein of hepatitis C virus' see figure 1 ---	1-8, 13
A	EP,A,0 442 394 (UNITED BIOMEDICAL INC) 21 August 1991 see page 47; claim 35 --- -/--	1-14
<p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
03 JUNE 1993	14 -06- 1993	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	SKELLY J.M.	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category ^a	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	LABORATORY INVESTIGATION vol. 65, no. 4, 1991, pages 408 - 411 Y. SHIEH ET AL. 'Detection of hepatitis C virus sequences in liver tissue by the polymerase chain reaction' see especially second PCR sense probe from core region page 411 ---	11
X	WO,A,9 014 436 (CHIRON CORPORATION) 29 November 1990 see claim 7 ---	7
X,P	WO,A,9 300 365 (CHIRON CORPORATION) 7 January 1993 see page 34, line 12 - line 15; claims 1-15 -----	1-10, 12-14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB93/00410

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark : Although claim 15 is directed to a method of treatment of
(diagnostic method practised on) the human/animal body the search has been
carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9300410
SA 70666

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03/06/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0442394	21-08-91	US-A- 5106726	21-04-92
		AU-B- 635124	11-03-93
		AU-A- 7439991	17-10-91
		EP-A- 0468527	29-01-92

WO-A-9014436	29-11-90	AU-A- 5812390	18-12-90
		CA-A- 2017157	18-11-90
		EP-A- 0398748	22-11-90
		JP-T- 5500155	21-01-93

WO-A-9300365	07-01-93	AU-A- 2305392	25-01-93
